Clomipramine use in obsessive-compulsive disorder

Expert Review of Neurotherapeutics

Volumn 2, Issue 6, 2002, Pages 783-790

  Ivey, Jennifer L ^a   Rosenberg, David R ^a  

^a UPC Jefferson   (United States)

Author keywords

Clomipramine; Obsessive compulsive disorder; Pharmacotherapy; Selective serotonin reuptake inhibitor; Serotonin reuptake inhibitor; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; CIMETIDINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HYDROCORTISONE; IMIPRAMINE; METHYLPHENIDATE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PROLACTIN; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANTICHOLINERGIC EFFECT; ATRIOVENTRICULAR BLOCK; BEHAVIOR THERAPY; BRADYCARDIA; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSTONIA; HEART ARRHYTHMIA; HEART DEATH; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LONG QT SYNDROME; MENTAL DISEASE; META ANALYSIS; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANIC; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEDATION; SINUS TACHYCARDIA; SUDDEN DEATH; TREATMENT OUTCOME; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0036844959     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.6.783     Document Type: Review

References (83)

1. Robins LN, Helzer JI, Weissman MM et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry 41, 949-958 (1984).
2. Flament MF, Whitaker A, Rapoport JL Obsessive compulsive disorder in adolescence: An epidemiological study. J. Am. Acad. Child Adolescent Psychiatry 27, 764-771 (1988).
3. Hanna GL. Demographic and clinical features of obsessive-compulsive disorder in children and adolescents. J. Am. Acad. Child Adolescent Psychiatry 34(1), 19-27 (1995).
4. Valleni-Basile LA, Garrison CZ, Jackson KL et al. Frequency of obsessive-compulsive disorder in a community sample of young adolescents. J. Am. Acad. Child Adolescent Psychiatry 33, 782-791 (1994).
5. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J. Clin. Psychiatry, 55(Suppl.), 5-14 (1994).
6. Karno MM, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch. Gen. Psychiatry 45, 1094-1099 (1988)
7. Calvocoressi L, Lewis B, Harris M et al. Family accommodation in obsessive-compulsive disorder. Am. J. Psychiatry 152, 441 (1995)
8. Rapoport JL, Leonard HL, Swedo SE, Lenane MC. Obsessive compulsive disorder in children and adolescents: Issues in management. J. Clin. Psychiatry 54(6 Suppl.), 27-30 (1993).
9. Swedo SE, Rapoport JL, Leonard H, Lenane M, Cheslow D. Obsessive-compulsive disorder in children and adolescents. Arch. Gen. Psychiatry 46, 335-341 (1989).
10. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A meta-analysis. Arch. Gen. Psychiatry 52, 53-60 (1995).
11. Hollander E, Kaplan A, Allen A, Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr. Clin. N. Am. 23(3), 643-656 (2000).
12. Ananth J. Clomipramine in obsessive-compulsive disorder: A review. Psychosomatics 24, 723-727 (1983).
13. Lopez-Ibor JJ. Ensayo clinico de la monochlorimipramina. Read at the Fourth World Congress of Psychiatry, Madrid, Spain (1966).
14. DeVeaugh-Geiss J, Moroz G, Biederman J et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder. A multicenter trial. J. Am. Acad. Child Adolesc. Psychiatry 31, 45-49 (1992). Provides finding for the use of clomipramine specific to children and adolescents.
15. DeVeaugh-Geiss J. Pharmacologic therapy of obsessive compulsive disorder. Adv. Pharmacol. 30, 35-52 (1994).
16. Rosenberg DR. Tricyclic Antidepressants. In: Pharmacotherapy for Child and Adolescent Psychiatric Disorders: Second Edition, Revised and Expanded. Rosenberg DR, Davanzo P, Gershon S (Eds), Marcel Dekker, New York, USA, 169-222 (2002). Comprehensive review of TCAs, including clomipramine.
17. Ward HE. The Newer Antidepressants. IM Internal Medicine 18(7), 65-76 (1997).
18. Potter WZ, Calil HM, Sutfin TA et al. Active metabolites of imipramine and desipramine in man. Clin. Pharmacol. Ther. 31(3), 393-401 (1982).
19. Preskorn SH, Jerovich GS, Beber JH, Widener P. Therapeutic drug monitoring of tricyclic antidepressants: A standard of case issue. Psychopharmacol. Bull. 25(2), 281-284 (1989).
20. Preskom SH, Weller EB, Weller RA, Glotzbach E. Plasma levels of imipramine and adverse effects in children. Am J Psychiatry 140(10), 1332-1335 (1983).
21. Sjoquist F, Bertilsson L. Clinical pharmacology of antidepressant drugs: Pharmacogenetics. Adv. Biochem. Psychopharmacol. 39, 359-372 (1984).
22. Ryan ND, Puig-Antich J, Cooper TB et al. Relative safety of single versus divided dose imipramine in adolescent major depression. J. Am. Acad. Child Adolesc. Psychiatry 26(3), 400-406 (1987).
23. Pigott TA, Seay SM. A review of the efficacy of selective serotonin re-uptake inhibitors in obsessive-compulsive disorder. J. Clin. Psychiatry 60, 101-110 (1999).
24. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive compulsive disorder: I. A controlled clinical trial. Arch. Gen. Psychiatry 37, 1281-1285 (1980).
25. Flament MF, Rapoport JL, Berg CJ et al. Clomipramine treatment of childhood obsessive compulsive disorder. A double-blind controlled study. Arch. Gen. Psychiatry 42, 977-983 (1985).
26. Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsive disorder. Depress. Anxiety 8 (Suppl. 1), 105-113 (1998).
27. Rosenberg DR. Selective Serotonin Reuptake Inhibitors. In: Pharmacotherapy for Child and Adolescent Psychiatric Disorders: Second Edition, revised and expanded. Rosenberg DR, Davanzo P, Gershon S (Eds), Marcel Dekker, New York, USA, 223-296 (2002).
28. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study. J. Clin. Psychopharmacol. 17, 267-271 (1997).
29. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with OCD. Arch. Gen. Psychiatry 48, 730-738 (1991). Shows support for the efficacy of clomipramine in OCD patients.
30. March J, Frances A, Kahn D, Carpenter D. Expert Consensus Guidelines: Treatment of obsessive-compulsive disorder. J. Clin. Psychiatry 58(Suppl. 4), 1-72 (1997). Provides comprehensive algorith for treatment of OCD.
31. Riddle MA, Reeve EA, Yaryura-Tobias JA et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial. J. Am. Acad. Child Adolesc. Psychiatry 40, 222-229 (2001).
32. March JS, Biederman J, Wolkow R et al. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. JAMA 280, 1752-1756 (1998).
33. Geller D, Coffey B, Rosenberg D, Carpenter D, Pauls D. Recent advances in pediatric obsessive compulsive and Tourette's disorders. Scientific Proceedings of the 4th Annual Meeting of the American Academy of Children and Adolescent Psychiatry 31, 68-69 (2001)
34. Geller DA, Carpenter DJ, Biederman J, Wagner K, Emslie G, Carpenter D. Comorbid psychiatric illness and response to paroxetine in pediatric OCD. Proceedings of the American Academy of Child and Adolescent Psychiatry. Honolulu, HI. October (2001).
35. Geller DA, Hoog SL, Heiligenstein JH et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 40(7), 773-779 (2001).
36. Emslie G, Judge R. Tricyclic antidepressants and selective serotonin re-uptake inhibitors: Use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr. Scand. Suppl. 403, 26-34 (2000).
37. Riddle MA, Scahill L, King RA et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J. Am. Acad Child Adolesc. Psychiatry 31(6), 1062-1069 (1992).
38. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br. J. Psychiatry 166, 424-443 (1995).
39. Stein DJ, Spadaccinni E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 10, 11-18 (1995).
40. Pigott TA, Pato MT, Bernstein SE et al. Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 47, 926-930 (1990).
41. Smeraldi E, Erzezovesi S, Bianchi I et al. Fluvoxamine versus clomipramine treatment in OCD: A preliminary study New Trends Expo. Clin. Psychiatry 8, 63-65 (1992).
42. Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: A multicenter, randomized, double-blind, parallel group comparison. J. Clin. Psychopharmacol. 55, 301-305 (1994).
43. Koran LM, McLeroy SI, Davidson JRT et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. J. Clin. Psychopharmacol. 16, 121-129 (1996).
44. Lopez-Ibor JJ Jr, Saiz J, Cottraux J et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 6(2), 111-118 (1996).
45. Bisserbe JC, Lane RM, Flament MF and the Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in out-patients with obsessive-compulsive disorder. Eur. Psychiatry 12, 82-93 (1997).
46. Zohar J, Judge R and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry 169, 468-474 (1996).
47. Flament MF, Bisserbe JC. Pharmacologic treatments of obsessive-compulsive disorder: Comparative studies. J. Clin. Psychiatry 58(12), 18-22 (1997).
48. Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am. J. Cardiol. 61, 501-509 (1988).
49. Baldessarini R. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th. Pergamon Press, New York, USA, 383-435 (1990).
50. Gutgesell H, Atkins D, Barst R et al. AHA scientific statement: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J. Am. Acad Child Adolesc. Psychiatry 38(8), 1047-1050 (1999).
51. Ryan N. Heterocydic antidepressants in children and adolescents. J Child Adolesc. Psychopharmacol. 1, 21-30 (1990).
52. Biederman J, Baldessarini R, Wright V, Knee D, Harmatz J, Goldblatt A. A double-blind placebo-controlled study of desipramine in the treatment of ADD, II: Serum drug levels and cardiovascular findings. J. Am. Acad. Child Adolesc. Psychiatry 28(903), 911 (1989).
53. Schroeder JS, Mullin AV, Elliott GR et al. Cardiovascular effects of desipramine in children [see comments]. J. Am. Acad. Child Adolesc. Psychiatry 28(3), 376-379 (1989).
54. Fletcher SE, Case CL, Sallee FR, Hand LD, Gillette PC. Prospective study of the electrocardiographic effects of imipramine in children. J. Pediatr. 122(4), 652-654 (1993).
55. Wilens T, Biederman J, Baldessarini R et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J. Am. Acad Child Adolesc. Psychiatry 35, 1491-1501 (1996).
56. Wilens T, Biederman J, Baldessarini R, Puopolo P, Flood J. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents and adults treated with desipramine. J. Am. Acad. Child Adolesc. Psychiatry 32, 798-804 (1993).
57. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J. Am. Acad Child Adolesc. Psychiatry 38(5), 513-516 (1999).
58. Walsh BT, Giardina EG, Sloan RP, Greenhill L, Goldfein J. Effects of desipramine on autonomic control of the heart. J. Am. Acad. Child Adolesc. Psychiatry 33(2), 191-197 (1994).
59. Mezzacappa E, Steingard R, Kindlon D, Saul JP, Earls F. Tricyclic antidepressants and cardiac autonomic control in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 37(1), 52-59 (1998).
60. Dugas M, Zarifian E, Leheuzey MF, Rovei V, Durand G, Morselli PL. Preliminary observations of the significance of monitoring tricyclic antidepressant plasma levels in the pediatric patient. Ther. Drug Monit. 2(4), 307-314 (1980).
61. Koran LM, Sallee FR, Pallanti S. Rapid benefit of iv. pulse loading of clomipramine in obsessive-compulsive disorder. Am. J. Psychiatry 154, 396-401 (1997). Provides insight on the benefits of intravenous clomipramine use.
62. Capstick N. Clomipramine in obsessional states. Psychosomatics 12, 332-335 (1971).
63. Rack PH. Clomipramine (Anafranil) in the treatment of obsessional states with special reference to the Leyton Obsessional Inventory. J. Int. Med. Res. 1, 397-402 (1973).
64. Rack PH. Clinical experience in the treatment of obsessional states, 2. J. Int. Med. Res. 5, 81-90 (1977).
65. Ribgy B, Clarren S, Kelly D. A psychological and physiological evaluation of the effects of iv. clomipramine (Anafranil). J. Int. Med. Res. 1, 308-316 (1973).
66. Faravelli C, Pallanti S. Clomipramine by different routes of administration: Short- and long-term efficacy and predictors of clinical outcome. Psychopharmacol. Bull. 23, 459-463 (1987).
67. Walter CS. Clinical impressions of treatment obsessional states with iv. clomipramine (Anafranil). J. Int. Med. Res. 1, 413-416 (1973).
68. Fallon BA, Campeas R, Schneier FR et al. Open trial of iv. clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J. Neuropsychiatry Clin. Neurosci. 4, 70-75 (1992).
69. Fallon BA, Liebowitz MR, Campeas R et al. Intravenous clomipramine for obsessive compulsive disorder refractory to oral clomipramine. Arch. Gen. Psychiatry 55(10), 918-924 (1998). Shows that intravenous clomipramine use can be effective in treatment refractory patients.
70. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive-compulsive disorder. J. Clin. Psychopharmacol. 14, 216-218 (1994).
71. Warneke LB. Intravenous clomipramine in obsessive-compulsive disorder. Can. J. Psychiatry 34, 853-859 (1989).
72. Warneke LB. Intravenous clomipramine in the treatment of obsessional disorder in adolescence: A case report. J. Clin. Psychiatry 46, 100-103 (1985).
73. Warneke LB. The use of iv. chlormipramine in the treatment of obsessive compulsive disorder. Can. J. Psychiatry 29, 135-141 (1984).
74. Mundo E, Bareggi SR, Pirola R, Bellodi L. Effect of acute iv. clomipramine and anti-obsessional response to proserotonergic drugs: Is gender a predictive variable? Biol. Psychiatry 45, 290-294 (1999).
75. Mundo E, Bellodi L, Smeraldi E. Effects of acute iv. clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Biol. Psychiatry 38, 525-531 (1995).
76. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of iv. clomipramine in obsessive-compulsive disorder. Eur. Neuropsychopharmacol. 8(2), 121-126 (1998). Provides comparison of methods of administration for intravenous clomipramine.
77. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: Predicting response to oral therapy at eight weeks. Biol. Psychiatry 44(3), 220-227 (1998).
78. Mathew SJ, Coplan JD, Perko KA et al. Neuroendocrine predictors of response to iv. clomipramine therapy for refractory obsessive-compulsive disorder. Depress. Anxiety 14(4), 199-208 (2001).
79. King RA, Leonard H, March J. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry 37(10), (1998).
80. Franklin ME, Kozak MJ, Cashman LA, Coles ME, Rheingold AA, Foa EB. Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: An open clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 37, 412-419 (1998).
81. March JS, Mulle K, Herbel B. Behavioral psychotherapy for children and adolescents with obsessive-compulsive disorder: An open trial of a new protocol-driven treatment package. J. Am. Acad. Child Adolesc. Psychiatry 33, 333-341 (1994).
82. Wever C, Rey JM. Juvenile obsessive-compulsive disorder. Aust. NZ J. Psychiatry 31, 105-113 (1997).
83. Davanzo P. Novel (Atypical) Antidepressants. In: Pharmacotherapy for Child and Adolescent Psychiatric Disorders: Second Edition, revised and expanded. Rosenberg DR, Davanzo P, Gershon S, Marcel Dekker, New York, USA, 297-316 (2002).